Selexis And Generium Launch Omalizumab Biosimilar In Russia
Xolair Rival Is Third Biosimilar Developed By Firms With SUREtechnology Platform
Executive Summary
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.
You may also be interested in...
Advanz Agrees Multi-Market Omalizumab Deal With Alvotech
Advanz and Alvotech have struck a deal that will give Advanz exclusive rights to the biosimilars developer’s Xolair (omalizumab) rival in multiple markets around the world.
Russia’s Binnopharm Brings In Mabwell’s Adalimumab, Denosumab Biosimilars
China’s Mabwell has furthered its strategy to bring its biosimilars to global markets “for the benefit of millions of patients around the world” via a licensing agreement with Russian player Binnopharm.
Aurobindo Expects To Be In Top Three For Immunology Biosimilar – Is It Xolair?
Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar, potentially a version of Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23.